Spyre Therapeutics, Inc. (SYRE) Stock
Healthcare · Biotechnology · Member of Other US Stocks
Spyre Therapeutics, Inc. (SYRE) closed at USD 80.10 on 2026-10-15, a change of +236.1 % over the past year, with a market capitalization of USD 7.47B.
Spyre Therapeutics, Inc. recent closing prices
| Date | Close (USD) |
|---|---|
| 2026-10-15 | 80.10 |
| 2026-10-14 | 78.63 |
| 2026-10-13 | 80.45 |
| 2026-10-12 | 85.90 |
| 2026-10-09 | 85.69 |
| 2026-10-08 | 79.90 |
| 2026-10-07 | 80.85 |
The most recent trading day is not shown. For full charts and indicators use the analysis page.
Spyre Therapeutics, Inc. key figures
- Previous close
- USD 80.10 (2026-10-15)
- 1-year change
- +236.1 %
- Market cap
- USD 7.47B
- Enterprise value
- USD 6.05B
- P/E ratio (trailing)
- -41.62
- P/E ratio (forward)
- -22.68
- EPS (trailing)
- -1.92
- EPS (forward)
- -3.52
- PEG ratio
- n/a
- Price to book
- 7.37
- Revenue growth
- n/a
- Earnings growth
- n/a
- Dividend per share (trailing)
- 0.00
- Short ratio
- 9.85
- Employees
- 125
- Analyst consensus (third-party)
- strong_buy
Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.
About Spyre Therapeutics, Inc.
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease); and SPY002 and SPY072 anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A). It is also developing SPY003, a clinical-stage program, which is in phase-2 clinical stage designed to bind to interleukin 23 (IL-23); SPY120, a combination of anti-a4ß7 and anti-TL1A mAbs; SPY130, a combination anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. The company was incorporated in 2013 and is based in Waltham, Massachusetts.
Technical indicators and comparison
Show RSI, MACD, EMA, CCI and ADX for Spyre Therapeutics, Inc. and compare it with other stocks.
Analyze SYREAll Other US Stocks stocksStock-scoring.com provides this page for information only. It is not investment advice or a recommendation to buy or sell Spyre Therapeutics, Inc. shares.